Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) saw unusually-high trading volume on Monday . Approximately 1,152,607 shares traded hands during mid-day trading, an increase of 55% from the previous session’s volume of 744,649 shares.The stock last traded at $47.61 and had previously closed at $46.96.

A number of equities research analysts have weighed in on the stock. ValuEngine upgraded shares of PTC Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Zacks Investment Research cut shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. William Blair reaffirmed a “buy” rating on shares of PTC Therapeutics in a report on Tuesday, November 26th. TheStreet upgraded shares of PTC Therapeutics from a “d” rating to a “c-” rating in a research report on Tuesday, October 29th. Finally, Barclays reissued a “hold” rating and issued a $43.00 target price on shares of PTC Therapeutics in a research note on Monday, August 12th. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $54.38.

The business has a 50-day simple moving average of $41.56 and a two-hundred day simple moving average of $41.85. The stock has a market capitalization of $3.07 billion, a P/E ratio of -26.94 and a beta of 1.90. The company has a quick ratio of 4.30, a current ratio of 4.40 and a debt-to-equity ratio of 0.44.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.15). The company had revenue of $71.40 million for the quarter, compared to analyst estimates of $72.03 million. PTC Therapeutics had a negative return on equity of 31.92% and a negative net margin of 74.86%. The business’s revenue was up 33.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.06) earnings per share. On average, sell-side analysts forecast that PTC Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. State of New Jersey Common Pension Fund D acquired a new stake in shares of PTC Therapeutics during the 3rd quarter worth about $1,809,000. Pictet Asset Management Ltd. lifted its holdings in PTC Therapeutics by 3.5% during the 3rd quarter. Pictet Asset Management Ltd. now owns 1,161,775 shares of the biopharmaceutical company’s stock valued at $39,291,000 after purchasing an additional 39,302 shares during the last quarter. Sector Gamma AS boosted its position in PTC Therapeutics by 17.8% in the second quarter. Sector Gamma AS now owns 229,498 shares of the biopharmaceutical company’s stock valued at $10,327,000 after buying an additional 34,755 shares in the last quarter. Aperio Group LLC acquired a new position in PTC Therapeutics in the second quarter valued at about $168,000. Finally, Russell Investments Group Ltd. boosted its position in PTC Therapeutics by 513.3% in the third quarter. Russell Investments Group Ltd. now owns 58,401 shares of the biopharmaceutical company’s stock valued at $1,975,000 after buying an additional 48,879 shares in the last quarter. 99.35% of the stock is currently owned by institutional investors and hedge funds.

PTC Therapeutics Company Profile (NASDAQ:PTCT)

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.

Recommended Story: What is a Real Estate Investment Trust (REIT)?

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.